Quest Diagnostics Incorporated’s Stock Price Drops to $184.64, Reflecting a 3.03% Decrease: A Deep Dive into DGX’s Market Performance

Quest Diagnostics Incorporated (DGX)

184.64 USD -5.77 (-3.03%) Volume: 2.89M

Quest Diagnostics Incorporated’s stock price stands at 184.64 USD, experiencing a trading session decline of 3.03%, amidst a trading volume of 2.89M. Despite the recent dip, DGX’s year-to-date performance shows a promising 22.39% increase, indicating robust market presence and potential for growth.

Latest developments on Quest Diagnostics Incorporated

Quest Diagnostics has been on a positive trajectory leading up to today’s stock price movements, with the company reporting strong financial results for the third quarter of 2025, surpassing earnings and revenue estimates. The company raised its guidance for the full year, citing strong revenue growth and strategic expansion initiatives. Quest Diagnostics also saw its stock price target raised by analysts, indicating confidence in the company’s performance. Despite a slide in shares following the earnings report, Quest Diagnostics remains a strong player in the diagnostic testing market, with promising outlook and strong clinical demand driving its earnings beat.

Quest Diagnostics Incorporated on Smartkarma

Analysts at Baptista Research on Smartkarma have been bullish on Quest Diagnostics, a leading player in the medical diagnostics sector. In their research report titled “Quest Diagnostics: Capitalizing On Advanced Diagnostics & Utilization Trends & Other Major Growth Drivers!”, they highlighted the company’s second-quarter 2025 results, which showed a significant 15.2% increase in consolidated revenues to $2.76 billion. This growth was attributed to heightened demand for advanced diagnostic solutions and expanded relationships with enterprise accounts.

In another report by Baptista Research, titled “Quest Diagnostics: Investment in Technology & Data Management For A Competitive Edge!”, analysts discussed the company’s strong performance in the first quarter of 2025. With a 12% increase in revenues driven by acquisitions, organic growth, and increased demand for advanced diagnostics, Quest Diagnostics is strategically focused on expanding its advanced diagnostics portfolio and leveraging automation and AI. The analysts aim to evaluate various factors influencing the company’s price and conduct an independent valuation using a Discounted Cash Flow (DCF) methodology.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics Incorporated, a company that provides diagnostic testing and services, has received a promising overall outlook based on the Smartkarma Smart Scores. With solid scores in Dividend and Momentum, the company is positioned well for long-term growth and stability. While the Value and Growth scores are moderate, Quest Diagnostics shows resilience in the face of challenges, indicating a strong foundation for future success.

Quest Diagnostics operates a national network of laboratories and patient service centers, offering a range of testing services. With a focus on esoteric testing, routine medical testing, and more, the company plays a crucial role in the healthcare industry. The positive Smart Scores suggest that Quest Diagnostics is well-positioned to continue providing essential diagnostic services and generate value for its investors in the long run.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma